Switch to:
More From Other Websites
Repros Announces the Issuance of New U.S. Patent Relating to Treatment Using Off Drug Intervals For... Apr 17 2017
Repros' Proellex Continues to be Under Partial Clinical Hold Apr 11 2017
Woodlands drug company names new top exec Apr 11 2017
Repros Therapeutics stock halted after FDA says partial clinical hold will continue for fibroids... Apr 10 2017
Repros Names Larry Dillaha, M.D., its Permanent President and CEO Apr 10 2017
Company Holds Meeting with FDA to Discuss Oral Proellex® in the Treatment of Uterine Fibroids Apr 10 2017
Repros Therapeutics reports 4Q loss Mar 31 2017
Repros Therapeutics Inc.® Reports Fourth Quarter and Year End 2016 Financial Results Mar 31 2017
Repros (RPRX) Q4 Earnings: What's in Store for the Stock? Mar 07 2017
Repros Announces New CEO Feb 02 2017
FDA Grants End of Phase 2 Meeting to Discuss Phase 3 Requirements for Oral Proellex® in the... Jan 30 2017
Repros to Meet with the FDA for Phase III Proellex Program Dec 13 2016
How Bonanza Creek Energy Inc (BCEI) Stacks Up In Relation to Its Peers Dec 13 2016
7 Companies That Destroyed Shareholders Last Week Dec 10 2016
Repros Therapeutics Drops on FDA Vote Dec 07 2016
10 Major Pharma and FDA Catalysts Coming in December Dec 05 2016
Repros (RPRX) Loss Narrower Y/Y in Q3, Pipeline in Focus Nov 09 2016

Add Notes, Comments

If you want to ask a question or report a bug, please create a support ticket.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK